Valion Bio (VBIO) Change in Receivables (2021 - 2025)
Valion Bio (VBIO) posted quarterly Change in Receivables of $6000.0 for Q3 2025, up 185.71% year-over-year from $2100.0 in Q3 2024, and up 110.71% quarter-over-quarter from -$56000.0 in Q1 2025.
Valion Bio (VBIO) Change in Receivables (2021 - 2025) Analysis & Trends
Valion Bio's Change in Receivables history runs 5 years deep, the most recent figure standing at $6000.0 for Q3 2025.
- In Q3 2025, Change in Receivables rose 185.71% year-over-year to $6000.0; the TTM figure through Sep 2025 stood at $5000.0 (up 103.68% YoY), while the FY2024 annual figure was -$105000.0, down 256.72% from the prior year.
- Change in Receivables for Q3 2025 stood at $6000.0, up from -$56000.0 in the prior quarter.
- The five-year high for Change in Receivables was $118000.0 in Q3 2023, with the low at -$100000.0 in Q1 2024.
- The 5-year median for Change in Receivables is -$2500.0 (2021), against an average of $250.0.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables soared 700.0% in 2023, then slumped 222.58% in 2024.
- Valion Bio's Change in Receivables stood at -$2000.0 in 2021, then sank by 100.0% to -$4000.0 in 2022, then jumped by 700.0% to $24000.0 in 2023, then surged by 129.17% to $55000.0 in 2024, then plunged by 89.09% to $6000.0 in 2025.
- Business Quant data shows VBIO's Change in Receivables at $6000.0 in Q3 2025, -$56000.0 in Q1 2025, and $55000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Valion Bio | 404,923.65 | -1.80 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Mar 31, 2025 | -56,000.00 |
| Mar 31, 2025 | -56,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Sep 30, 2023 | 118,000.00 |
| Sep 30, 2023 | 118,000.00 |
| Jun 30, 2023 | -44,000.00 |
| Jun 30, 2023 | -44,000.00 |
| Mar 31, 2023 | -31,000.00 |
| Mar 31, 2023 | -31,000.00 |